SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors anticipate upcoming earnings and potential hyperscaler announcements, crucial for the company's AI infrastructure growth. Community discussions revolve around the timing of a new lease and the impact of Macquarie's recent funding draw. Bullish sentiment remains high due to the expected increase in AI data center demand and APLD's strategic position.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending due to a strategic partnership to develop 'Made in US' post-quantum cryptography solutions for US government and defense, sparking bullish sentiment. The community is actively discussing the potential for a short squeeze and significant upside, drawing comparisons to other quantum stocks. With high trading volume and positive news, investors are optimistic about the company's future growth and potential double-digit price targets.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending due to a significant surge fueled by new AI partnerships with industry leaders like OpenAI, Google, NVIDIA, and Snowflake. The community is buzzing about the company's shift towards agentic automation and its potential to become a central player in enterprise AI, drawing comparisons to Palantir ($PLTR). Many believe $PATH has been undervalued and are anticipating further gains, citing its strong cash position and strategic partnerships as catalysts for future growth.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf ($WULF) is trending as investors discuss a potential short squeeze, fueled by its high short interest and growing optimism around its transition to AI and high-performance computing. Community members are pointing to the stock's setup mirroring past breakouts, while also highlighting analyst price targets and the increasing open interest in call options. Some are closely watching for news regarding the Lake Cayuga site approval, which could act as a further catalyst.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices approach multi-decade highs, sparking discussions about a potential breakout. Community members are debating whether demand is crushing short positions and anticipating further gains, with some pointing to a possible short squeeze. The broader context involves rising interest in precious metals as a hedge against economic uncertainty, amplified by a potentially weaker dollar and a possible government shutdown.

TOSHI

TOSHI is trending as the community rallies behind the token, pointing to strong chart patterns and increasing volume. Many are drawing comparisons to previous meme coin surges, speculating on potential listings on major exchanges like Robinhood and Binance. The community emphasizes its strong organic growth and active engagement.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending amid discussions about defense spending, potential contract wins, and comparisons to other high-growth tech and defense companies. The community is actively debating its valuation, potential for acquisitions, and upcoming catalysts like government contracts and drone technology advancements. Some traders are taking profits after a significant run-up, while others see it as a long-term growth play.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending amid increased Bitcoin production and expansion into AI cloud services, sparking community excitement around its potential in both sectors. Some investors are drawing comparisons to IREN, while others highlight HIVE's strong assets and growing hashrate, anticipating further upward momentum. Discussions also focus on potential partnerships and undervaluation relative to peers.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending as investors discuss its growth potential in the autonomous delivery market, especially following recent acquisitions and partnerships with major platforms like DoorDash and Uber Eats. Community members are weighing the stock's valuation and future prospects, noting the high short interest and potential for a squeeze. Bullish sentiment is fueled by expectations of revenue growth and expansion into new markets, although some caution against potential pullbacks.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors actively discuss the potential impact of data center constraints and new partnerships on the company's growth. Community members are speculating about upcoming news and potential deals, particularly related to its stake in Clickhouse and its role in AI infrastructure. The stock's volatility and potential for significant gains are also prominent talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem (VSTM) Upgraded to Buy: Here's What You Should Know

Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of +54.12% and -86.36%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

Gossamer Bio (GOSS) delivered earnings and revenue surprises of +5.56% and +155.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?  

Shares of Verastem Oncology (VSTM) dropped 19% on Monday despite the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-updated-data-partner-genfleet">announcing</a> positive updated data from the dose escalation phase of its trial for cancer therapy GFH375, conducted by its partner, GenFleet Therapeutics.In a study in China, GFH375, also known as VS-7375 in the U.S., demonstrated an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and a response rate of 42% in those with non-small cell lung cancer, the company stated.Verastem stated that data from its partner supports the advancement of its clinical program for VS-7375 in the U.S., which is slated to start in mid-2025.The company is activating sites in the U.S. for VS-7375 to begin enrollment in the trial. The study has the potential to expand globally and will evaluate the safety and efficacy of VS-7375 in patients with advanced, KRAS G12D-mutant solid tumors.The KRAS G12D mutation, a genetic alteration in the KRAS gene, is common in various cancers, particularly pancreatic cancer, colorectal cancer, and lung adenocarcinoma.As part of the collaboration between Verastem and GenFleet, Verastem has development and commercialization rights for the cancer therapy outside the GenFleet markets of mainland China, Hong Kong, Macau, and Taiwan.On Stocktwits, retail sentiment around Verastem rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_12_42_50_PM_png_7c68caaf50.webp" alt="VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 2, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock could be tanking owing to the Chinese partnership.<stembedurl>https://stocktwits.com/Universaal/message/616509493</stembedurl>According to data from Koyfin, all of the nine analysts covering the stock rate it ‘Buy’ or higher. The stock has an average price target of $15.75, representing an upside of over 150%.<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> is down by 6% this year but up by about 55% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-s-push-toward-fully-automated-ads-to-reportedly-debut-by-year-end/chkY2oMRbHJ">Meta’s Push Toward Fully Automated Ads To Reportedly Debut By Year-End</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell lung cancer.

Equity

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

The U.S. Food and Drug Administration on Thursday granted accelerated approval to Verastem Oncology’s (VSTM) combination therapy for adult patients with a particular type of ovarian cancer.The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low">treat</a> patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.LGSOC is a rare ovarian cancer which is highly recurrent and less sensitive to chemotherapy compared to high-grade serous ovarian cancer. Approximately 6,000-8,000 women in the U.S. and 80,000 worldwide are living with this disease, as per Verastem.Avmapki Fakzynja Co-pack is the first and only FDA-approved medicine for this disease, Verastem said, while adding that the oral medicine pack is expected to be available for adult patients in the U.S. in one week.The FDA previously granted priority review to Verastem’s drug application and also designated it a breakthrough therapy and orphan drug.Late last month, the company announced a $75 million private placement. The proceeds would be used to fund the launch of the combination therapy, among other things. &nbsp;On Stocktwits, retail sentiment around Verastem rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:626/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_08_at_1_01_06_PM_png_213d5d0710.webp" alt="VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on May 8, 2025 | Source: Stocktwits" width="626" height="63"><figcaption>VSTM's Sentiment Meter and Message Volume as of 1:00 p.m. ET on May 8, 2025 | Source: Stocktwits</figcaption></figure>The stock is trading 3% higher on Thursday afternoon after a trading halt.&nbsp;<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> has gained by about 6% this year but has fallen by about 39% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/viatris-reports-q1-earnings-above-estimates/chifqcaRbk1">Viatris Q1 Earnings Exceed Wall Street Expectations, Company Raises Full-Year Profit Outlook: Retail’s Positive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased

The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster...

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will...

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VSTM News

VSTM Verastem Inc